Amarpreet Sawhney - Ocular Therapeutix Founder, Chairman, CEO and Pres
| OCUL Stock | USD 5.22 0.64 10.92% |
Chairman
Dr. Amarpreet Sawhney, Ph.D. is no longer Executive Chairman of the Board of the Company, effective July 26, 2019. He has served as the Chairman of our board of directors since June 2014. From 2008 to April 2014, Dr. Sawhney also served as Chief Executive Officer of Augmenix, Inc., a biopharmaceutical company, which was, up until April 2014, an affiliate of Ocular through Dr. Sawhneys service as Chief Executive Officer of both entities. Dr. Sawhney is also a general partner of Incept, LLC, an intellectual property holding company. Prior to joining Ocular Therapeutix, Dr. Sawhney founded and served as the President and Chief Executive Officer of Confluent Surgical, Inc., a medical device company, from 1998 to 2006 when it was acquired by Covidien plc. He served as a member of the board of directors of AccessClosure, Inc., a medical device company, from 2002 to 2009. Previously, he was a technical founder of Focal, Inc., a biopharmaceutical company subsequently acquired by Genzyme Corporation
| Age | 50 |
| Address | 15 Crosby Drive, Bedford, MA, United States, 01730 |
| Phone | 781 357 4000 |
| Web | https://www.ocutx.com |
Ocular Therapeutix Management Efficiency
The company has return on total asset (ROA) of (0.2566) % which means that it has lost $0.2566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2764) %, meaning that it created substantial loss on money invested by shareholders. Ocular Therapeutix's management efficiency ratios could be used to measure how well Ocular Therapeutix manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.34. The value of Return On Capital Employed is expected to slide to -0.4. At this time, Ocular Therapeutix's Other Current Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 243.8 M this year, although the value of Non Current Assets Total will most likely fall to about 11.8 M.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| William Rastetter | Neurocrine Biosciences | 69 | |
| Richard Pops | Alkermes Plc | 62 | |
| Arnold Oronsky | Dynavax Technologies | 77 | |
| Bryan Roberts | Ironwood Pharmaceuticals | 47 | |
| Jay Moorin | Eagle Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.26 |
Ocular Therapeutix Leadership Team
Elected by the shareholders, the Ocular Therapeutix's board of directors comprises two types of representatives: Ocular Therapeutix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ocular. The board's role is to monitor Ocular Therapeutix's management team and ensure that shareholders' interests are well served. Ocular Therapeutix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ocular Therapeutix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Naymisha Patel, Vice President - Quality | ||
| Pravin MD, Executive Chairman | ||
| Jaswinder Chadha, Director | ||
| Bruce Peacock, Independent Director | ||
| Michael Goldstein, Chief Medical Officer | ||
| Philip Esq, General Counsel | ||
| James Garvey, Independent Director | ||
| Rabia MD, Chief Officer | ||
| Steve Klass, IR Contact Officer | ||
| Antony Mattessich, President CEO, Director | ||
| Christopher White, Senior Vice President Head of Business and Corporate Development | ||
| Kevin Hanley, Senior Vice President - Technical Operations | ||
| Andy Hurley, Chief Commercial Officer | ||
| Amarpreet Sawhney, Founder, Chairman, CEO and Pres | ||
| Tracy Smith, Vice Resources | ||
| Jeffrey MD, Chief Officer | ||
| James OShea, Director | ||
| Scott Corning, VP Commercial | ||
| Charles Warden, Independent Director | ||
| Steve Meyers, Senior Commercial | ||
| KarenLeigh MBA, Senior Operations | ||
| Jeffrey Heier, Director | ||
| Bradford Smith, CFO | ||
| William II, Vice Marketing | ||
| James Fortune, COO | ||
| Daniel Bollag, Senior Vice President - Regulatory Affairs, Pharmacovigilance and Quality | ||
| Peter MD, Chief Retina | ||
| Donald Notman, Chief Officer | ||
| Patricia Kitchen, Chief Operations Officer | ||
| George Migausky, Interim CFO | ||
| Jonathan Talamo, Chief Medical Officer | ||
| Peter Jarrett, Chief Officer | ||
| Leslie Williams, Director | ||
| Richard Lindstrom, Independent Director | ||
| Eric Ankerud, Executive VP of Clinical, Regulatory and Quality | ||
| Philip Strassburger, G Counsel |
Ocular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ocular Therapeutix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.38) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | 758.54 M | ||||
| Shares Outstanding | 148.63 M | ||||
| Shares Owned By Insiders | 3.68 % | ||||
| Shares Owned By Institutions | 50.03 % | ||||
| Number Of Shares Shorted | 11.81 M | ||||
| Price To Earning | (2.69) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Ocular Stock analysis
When running Ocular Therapeutix's price analysis, check to measure Ocular Therapeutix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocular Therapeutix is operating at the current time. Most of Ocular Therapeutix's value examination focuses on studying past and present price action to predict the probability of Ocular Therapeutix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocular Therapeutix's price. Additionally, you may evaluate how the addition of Ocular Therapeutix to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Ocular Therapeutix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.02) | Revenue Per Share 0.732 | Quarterly Revenue Growth 0.052 | Return On Assets (0.26) | Return On Equity (1.28) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.